c*******r
发帖数: 6971 | 1 WASHINGTON (AP) -- The Food and Drug Administration on Tuesday approved
Amgen
's bone strengthening drug, Prolia, for postmenopausal women at risk for
fractures, a potential blockbuster market.
The injectable drug is given once every six months to increase bone mass
and strength.
Analysts think Prolia should bring Amgen billions in revenue after it is
launched. Sales of the company's former top sellers, the anemia drugs,
Aranesp
and Epogen, have dropped in recent years due to safety concerns and label
restrictions.
Pill-based osteoporosis drugs, such as Fosamax and Zometa, have been
available
for more than a decade. But Amgen Executive Vice President Dr. Roger
Perlmutter
said many women can't tolerate those drugs or have trouble remembering to
take a daily medication.
Amgen said in a statement that Prolia is the first drug to target a cellular
pathway that breaks down bones.
One out of every two women over age 50 will break a bone in their lifetime
due to osteoporosis, which causes bones to become brittle, according to
an FDA statement.
An analysis cited by Amgen estimates that osteoporosis-related fractures
will cost the U.S. health care system $25 billion annually by 2025.
FDA approved the drug based on a 7,000 patient study conducted by Amgen that
showed reduced vertebrae and hip fractures in postmenopausal women.
Common side effects with the drug included back pain, high cholesterol and
urinary bladder infections.
Thousand Oaks, Calif.-based Amgen will be required to distribute patient
guides explaining the drug's risks.
Global sales of osteoporosis treatments topped $8 billion last year,
including
hundreds of vitamin brands and drugs like GlaxoSmithKline PLC's Boniva and
Merck & Co. Inc.'s Fosamax.
With eight other pills and injectable medicines on the market, analysts say
Prolia's success likely will hinge on its price.
Prolia will cost $825 per injection, which the Amgen says is competitive
with existing treatments.
Shares of Amgen rose $1.74, or 3.4 percent, to $50.76 in afterhours trading
. |
y***q
发帖数: 4147 | 2 最近版上好象也没人玩生拉了，大牛们都到哪里去了。 |
c*******r
发帖数: 6971 | 3 感觉这个好像还不错，目前价格是52week最低点
加上这么个消息，怎么也得涨一点吧？
盘后涨了两块
【在 y***q 的大作中提到】
: 最近版上好象也没人玩生拉了，大牛们都到哪里去了。
|
y***q
发帖数: 4147 | |
c*******r
发帖数: 6971 | 5 看了一下，白天买点@55的call好了，才0.26
【在 c*******r 的大作中提到】
: 感觉这个好像还不错，目前价格是52week最低点
: 加上这么个消息，怎么也得涨一点吧？
: 盘后涨了两块
|
c*******r
发帖数: 6971 | 6 AMGN
刚刚yahoo finance的头条
【在 y***q 的大作中提到】
: pick是啥啊，看了半天没看到字母
|
y***q
发帖数: 4147 | |
c*******r
发帖数: 6971 | 8 好像比较坚挺，从05年到现在，最便宜的时候是08年3月，在41左右
【在 y***q 的大作中提到】
: 真贵的生垃啊
|
y***q
发帖数: 4147 | 9 mm可真坏啊，今天故意那么跳一下子，估计好多人都吓的下船了
【在 c*******r 的大作中提到】
: 好像比较坚挺，从05年到现在，最便宜的时候是08年3月，在41左右
|
u****d
发帖数: 23938 | 10 amgn好像是大牛古吧
【在 y***q 的大作中提到】
: 最近版上好象也没人玩生拉了，大牛们都到哪里去了。
|
y***q
发帖数: 4147 | 11 嗯，是的，看着很牛的样子，去年三月份都只跌到40块
【在 u****d 的大作中提到】
: amgn好像是大牛古吧
|
u****d
发帖数: 23938 | 12 和我的gild有的一拼；
哎，gild 捂了快4年又要回到起点了。。。
【在 y***q 的大作中提到】
: 嗯，是的，看着很牛的样子，去年三月份都只跌到40块
|
c*******r
发帖数: 6971 | 13 我靠啊，55 call涨到1.25了， 5X啊！！！
可惜不知道这个日程，因为10个contract昨天也就260，清零也可以接受
【在 c*******r 的大作中提到】
: 看了一下，白天买点@55的call好了，才0.26
|
c*******r
发帖数: 6971 | 14 这个股票今天继续涨啊，牛
【在 y***q 的大作中提到】
: pick是啥啊，看了半天没看到字母
|
